Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Molecular alterations in lung cancer. Impact on prognosis.
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Molecular alterations in lung cancer. Impact on prognosis.
Molecular alterations in lung cancer. Impact on prognosis. Methods Mol Med. 2003; 75:29-38.
View in:
PubMed
subject areas
Animals
Cell Transformation, Neoplastic
Chromosome Aberrations
Disease Models, Animal
Genes, Tumor Suppressor
Humans
Lung Neoplasms
Mice
Molecular Biology
Prognosis
Proto-Oncogene Proteins
Telomerase
authors with profiles
Ravi Salgia